Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery

Journal of Parkinson's Disease

Volumn 4, Issue 4, 2014, Pages 591-598

  Hack, Nawaz ^a   Akbar, Umer ^a   Thompson Avila, Amanda ^a   Fayad, Sarah M ^a   Hastings, Erin M ^a   Moro, Elena ^b   Nestor, Kelsey ^a   Ward, Herbert ^a   York, Michele ^c   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

compulsive behaviors; deep brain stimulation; dopamine dysregulation syndrome; impulsive behaviors; Parkinson's disease; psychosis

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; QUETIAPINE;

ARTICLE; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; DOPAMINE AGONIST WITHDRAWAL SYNDROME; DOPAMINE DYSREGULATION SYNDROME; EVALUATION STUDY; HEALTH SURVEY; HUMAN; IMPULSE CONTROL DISORDER; INTERVIEW; PARKINSON DISEASE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PREVALENCE; PSYCHOLOGIC TEST;

EID: 84914688193     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-140357     Document Type: Article

References (52)

1. Leeman RF, Billingsley BE, Potenza MN(2012) Impulse control disorders in Parkinson's disease: Background and update on prevention and management. Neurodegener Dis Manag, 2, 389-400.
2. Leeman RF, & Potenza MN (2011) Impulse control disorders in Parkinson's disease: Clinical characteristics and implications. Neuropsychiatry (London), 1, 133-147.
3. Raja M, & Bentivoglio AR (2012) Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders. Curr Drug Saf, 7, 63-75.
4. Weintraub D, & Nirenberg MJ (2013) Impulse control and related disorders in Parkinson's disease. Neurodegener Dis, 11, 63-71.
5. Weintraub D, Papay K, & Siderowf A (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study. Neurology, 80, 176-180.
6. Wu K, Politis M, & Piccini P (2009) Parkinson disease and impulse control disorders: A review of clinical features, pathophysiology and management. Postgrad Med J, 85, 590-596.
7. Potenza MN, Voon V, & Weintraub D (2007) Drug Insight: Impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol, 3, 664-672.
8. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, & Lang AE (2010) Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol, 67, 589-595.
9. Adler CH (2005) Nonmotor complications in Parkinson's disease. Mov Disord, 20(Suppl 11), S23-S29.
10. O'Sullivan SS, Evans AH, & Lees AJ (2009) Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs, 23, 157-170.
11. Temel Y, Kessels A, Tan S, Topdag A, Boon P, & Visser-Vandewalle V (2006) Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: A systematic review. Parkinsonism Relat Disord, 12, 265-272.
12. Perozzo P, Rizzone M, Bergamasco B, Castelli L, Lanotte M, Tavella A, Torre E, & Lopiano L (2001) Deep brain stimulation of subthalamic nucleus: Behavioural modifications and familiar relations. Neurol Sci, 22, 81-82.
13. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Koller WC, & Olanow CW (2009) Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol, 16, 493-497.
14. Moum SJ, Price CC, Limotai N, Oyama G,Ward H, Jacobson C, Foote KD,&Okun MS(2012) Effects ofSTNand GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One, 7, e29768.
15. Piano AN, & Tan LC (2013) Impulse control disorder in a patient with X-linked dystonia-parkinsonism after bilateral pallidal deep brain stimulation. Parkinsonism Relat Disord, 19, 1069-1070.
16. Kim YE, Kim HJ, Lee JY, Yun JY, Kim JY, Paek SH, & Jeon BS(2013) Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. J Clin Neurosci, 20, 964-969.
17. Eusebio A, Witjas T, Cohen J, Fluchère F, Jouve E, Régis J, & Azulay JP (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry, 84, 868-874.
18. Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, Lyons KE, Troster AI,Vitek JL, Tagliati M,&Group SDS (2012) Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: An open-label randomised controlled trial. Lancet Neurol, 11, 140-149.
19. Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, Follett KA, Reda D, Weaver FM, & Group CSPS (2013) Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: Results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry, 84, 1113-1118.
20. Okun MS, Fernandez HH, Wu SS, Kirsch-Darrow L, Bowers D, Bova F, Suelter M, Jacobson CET, Wang X, Gordon CW Jr, Zeilman P, Romrell J, Martin P, Ward H, Rodriguez RL, & Foote KD (2009) Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE trial. Ann Neurol, 65, 586-595.
21. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, Huang GD, & Group CSPS (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. JAMA, 301, 63-73.
22. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, Lees AJ, O'Sullivan DJ, Peppard RF, Rodrigues JP, Schrag A, Silberstein P, Tisch S, & Evans AH (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci, 16, 1148-1152.
23. Lawrence AD, Evans AH, & Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson's disease: Reward systems gone awry Lancet Neurol, 2, 595-604.
24. Ceravolo R, Frosini D, Rossi C, & Bonuccelli U (2009) Impulse control disorders in Parkinson's disease: Definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord, 15(Suppl 4), S111-S115.
25. Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F,Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, & Bonuccelli U (2013) A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: Association with dopaminergic drugs. J Clin Psychopharmacol, 33, 691-694.
26. Burdick AP, Foote KD, Wu S, Bowers D, Zeilman P, Jacobson CE, Ward HE, & Okun MS (2011) Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation. Neuroimage, 54, S227-S232.
27. Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, Follett KA, Reda D, & Weaver FM (2013) Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: Results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry, 84, 1113-1118.
28. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, ContarinoMF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, & de Bie RM (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): A randomised controlled trial. Lancet Neurol, 12, 37-44.
29. Rodrigues AM, Rosas MJ, Gago MF, Sousa C, Fonseca R, Linhares P, Basto MA, Sousa G, Garrett C, & Vaz R (2010) Suicide attempts after subthalamic nucleus stimulation for Parkinson's disease. Eur Neurol, 63, 176-179.
30. Porat O, Cohen OS, Schwartz R, & Hassin-Baer S (2009) Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci, 21, 398-405.
31. Weintraub D, Duda JE, Carlson K, Luo P, Sagher O, Stern M, Follett KA, Reda D,Weaver FM, & Group CS (2013) Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: Results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry, 84, 1113-1118.
32. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, & Voon V (2009) Validation of the questionnaire for impulsivecompulsive disorders in Parkinson's disease. Mov Disord, 24, 1461-1467.
33. Thomas A, Bonanni L, Gambi F, Di Iorio A, & Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol, 68, 400-404.
34. Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, & Okun MS (2013) Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol, 260, 521-527.
35. Rotondo A, Bosco D, Plastino M, Consoli A, & Bosco F (2010) Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord, 25, 1994-1995.
36. Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, & David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 80, 792-799.
37. Burbaud P, Clair AH, Langbour N, Fernandez-Vidal S, Goillandeau M, Michelet T, Bardinet E, Chereau I, Durif F, Polosan M, Chabardes S, Fontaine D, Magnie-Mauro MN, Houeto JL, Bataille B, Millet B, Verin M, Baup N, Krebs MO, Cornu P, Pelissolo A, Arbus C, Simonetta-Moreau M, Yelnik J,Welter ML,&Mallet L (2013) Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive-compulsive disorder. Brain, 136, 304-317.
38. Wylie SA, Ridderinkhof KR, Elias WJ, Frysinger RC, Bashore TR, Downs KE, van Wouwe NC, & van den Wildenberg WP (2010) Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain, 133, 3611-3624.
39. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, D'Ambrosia J, Thobois S, Tamma F, Herzog J, Speelman JD, Samanta J, Kubu C, Rossignol H, Poon YY, Saint-Cyr JA, Ardouin C, & Moro E (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain, 131, 2720-2728.
40. Maier F, Lewis CJ, Horstkoetter N, Eggers C, Kalbe E, Maarouf M, Kuhn J, Zurowski M, Moro E, Woopen C, & Timmermann L (2013) Patients' expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: A mixed-method approach. J Neurol Neurosurg Psychiatry, 84, 1273-1281.
41. Freund HJ (2005) Long-term effects of deep brain stimulation in Parkinson's disease. Brain, 128, 2222-2223.
42. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, & Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med, 349, 1925-1934.
43. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, & Van Blercom N (2005) Bilateral deep brain stimulation in Parkinson's disease: A multicentre study with 4 years follow-up. Brain, 128, 2240-2249.
44. Rodriguez-Oroz MC, Zamarbide I, Guridi J, Palmero MR, & Obeso JA(2004) Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: Double blind and open label evaluation. J Neurol Neurosurg Psychiatry, 75, 1382-1385.
45. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, & Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up. Neurology, 58, 396-401.
46. Houeto JL, Mesnage V,Welter ML, Mallet L, Agid Y, Bejjani BP(2003) SubthalamicDBSreplaces levodopa in Parkinson's disease: Two-year follow-up. Neurology 60, 154-155; author reply 154-155.
47. Lulé D, Heimrath J, Pinkhardt EH, Ludolph AC, Uttner I, & Kassubek J (2012) Deep brain stimulation and behavioural changes: Is comedication the most important factor Neurodegener Dis, 9, 18-24.
48. Okun MS, Wu SS, Foote KD, Bowers D, Gogna S, Price C, Malaty I, Rodriguez RL, Jacobson CE, Ward H (2011) Do stable patients with a premorbid depression history have a worse outcome after deep brain stimulation for Parkinson disease Neurosurgery 69, 357-360; discussion 360-351.
49. Timmermann L, Schupbach M, Hertel F, Wolf E, Eleopra R, Franzini A, Servello D, Skogseid IM, Rumia J, Aliaga AS, Barbe MT, Pauls KA, Lin JP, Moro E, Lloyd A,&MaaroufM (2013) A new rechargeable device for deep brain stimulation: Aprospective patient satisfaction survey. Eur Neurol, 69, 193-199.
50. Abosch A, Timmermann L, Bartley S, Rietkerk HG, Whiting D, Connolly PJ, Lanctin D, & Hariz MI (2013) An international survey of deep brain stimulation procedural steps. Stereotact Funct Neurosurg, 91, 1-11.
51. Mendelsohn D, Lipsman N, Lozano AM, Taira T,&Bernstein M (2013) The contemporary practice of psychiatric surgery: Results from a global survey of functional neurosurgeons. Stereotact Funct Neurosurg, 91, 306-313.
52. Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, &Whiteford HA (2013) The epidemiological modelling of major depressive disorder: Application for the global burden of disease study 2010. PLoS One, 8, e69637.